Focus Shifts to Metabolic Health Amid Industry Challenges

Wellness company Medifast (NYSE:MED) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 36.2% year on year to $89.41 million. On the other hand, next quarter’s revenue guidance of $72.5 million was less impressive, coming in 1.8% below analysts’ estimates. Its GAAP loss of $0.21 per share was 41.7% above analysts’ consensus estimates.

Is now the time to buy MED? Find out in our full research report (it’s free for active Edge members).

Revenue: $89.41 million vs analyst estimates of $89.7 million (36.2% year-on-year decline, in line)
EPS (GAAP): -$0.21 vs analyst estimates of -$0.36 (41.7% beat)
Adjusted EBITDA: -$3.14 million vs analyst estimates of -$4.1 million (-3.5% margin, relatively in line)
Revenue Guidance for Q4 CY2025 is $72.5 million at the midpoint, below analyst estimates of $73.8 million
EPS (GAAP) guidance for Q4 CY2025 is $0.98 at the midpoint, beating analyst estimates by 317%
Operating Margin: -4.6%, down from 1.5% in the same quarter last year
Market Capitalization: $122 million

Medifast’s third quarter results met Wall Street’s revenue expectations, but the market responded negatively as sales continued to decline sharply year-over-year. Management attributed these results to ongoing headwinds in the weight loss industry—most notably, increased competition from GLP-1 medications and declines in the number of active earning coaches. CEO Dan Chard highlighted that the company’s evolving science-backed approach to metabolic health aims to differentiate Medifast in a changing landscape. Chard pointed to coach-led support and recent clinical studies as key elements, while also acknowledging the need for further progress in reversing declining sales.

Looking forward, Medifast’s guidance reflects management’s belief that the company’s transformation toward metabolic health solutions will take time to gain traction. Chard said, “We’re evolving Medifast from being seen primarily as a weight loss company to one that is recognized as a leader in the broader field of metabolic health.” Leadership emphasized the upcoming launch of new products based on metabolic synchronization science and continued investments in coach training and digital tools. Management remains cautious about consumer spending and the timeline for a return to growth, pointing to coach productivity stabilization as an early indicator of potential improvement.

Medifast’s management cited several major factors behind the quarter’s performance and outlined ongoing efforts to reposition the company for long-term growth amid industry disruption.

GLP-1 medication impact: The rapid adoption of GLP-1 drugs for weight loss has shifted market dynamics, as CEO Dan Chard explained these medications are reshaping public perception but often lack long-term health benefits unless paired with lifestyle changes. Medifast is positioning its programs as complementary to or alternatives for GLP-1 usage.
Metabolic health repositioning: Management is steering the company from a traditional weight loss focus to address broader metabolic health challenges. Recent clinical studies showed Medifast’s program helped clients retain 98% of lean mass and reduce visceral fat, marking a shift in how success is measured.
Coach network evolution: The company’s coach community remains central, with 61% now supporting clients who have used GLP-1 medications. Training on new science and messaging is ongoing, as noted by Chief Field Operations Officer Nick Johnson, aiming to ensure consistent communication and effective client support.
Product innovation pipeline: A new product line based on metabolic synchronization and next-generation ingredients is set for launch next year, designed to improve the effectiveness of Medifast’s current offerings and reinforce its differentiation in the market.
Operational adjustments: Cost controls and business “rightsizing” were implemented, including reductions in coach compensation and SG&A expenses. CFO Jim Maloney noted the company maintains a strong balance sheet with no debt and over $170 million in cash and investments, providing flexibility during this transitional period.

Medifast’s outlook is shaped by continued industry disruption from GLP-1 drugs, a strategic pivot toward metabolic health, and efforts to stabilize its coach network.

GLP-1 headwinds and integration: Management expects GLP-1 medications to remain a major headwind, but believes Medifast’s programs can complement users transitioning off these drugs. The company is training coaches to address the distinct needs of clients on or moving away from GLP-1s, aiming to capture demand for sustainable, lifestyle-based solutions.
Coach productivity and network stability: Stabilizing and eventually growing coach productivity is a central pillar for future revenue recovery. Maloney indicated that a sustained increase in revenue per active coach could precede broader coach network expansion and eventual top-line growth, though this process is expected to take several quarters.
Product and digital initiatives: The planned launch of new metabolic health products and enhancements to digital platforms are intended to drive client engagement and retention. Management views these initiatives as critical for differentiating Medifast’s value proposition in a competitive, rapidly evolving market.

Going forward, the StockStory team will be monitoring (1) progress in stabilizing and growing coach productivity and network size, (2) the reception and impact of the upcoming metabolic health product launch, and (3) the effectiveness of ongoing training and digital enhancements in supporting client engagement and retention. Shifts in the broader weight loss industry, especially concerning GLP-1 adoption, will also remain key factors for future results.

Medifast currently trades at $11.59, down from $11.90 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free for active Edge members).

Fresh US-China trade tensions just tanked stocks—but strong bank earnings are fueling a sharp rebound. Don’t miss the bounce.

Don’t let fear keep you from great opportunities and take a look at Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

link